HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) but has lowered the price target from $15 to $8.

March 21, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barinthus Biotherapeutics' price target has been lowered from $15 to $8 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in the price target for Barinthus Biotherapeutics by HC Wainwright & Co. could lead to a negative short-term impact on the stock's price. This adjustment reflects a change in the analyst's valuation of the company, which could influence investor sentiment and potentially lower the stock price in the short term. However, the maintenance of a Buy rating indicates a positive outlook on the company's long-term potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100